2 results
Approved WMOCompleted
primaryTo assess the safety and tolerability of multiple, once-daily oral doses of RDN-929 over 28 days in healthy older adult subjects and early symptomatic AD subjects.secondaryTo assess the plasma and CSF pharmacokinetics (PK) of RDN-929 in…
Approved WMOPending
The HOPE-3 trial will evaluate the effects of lipid modification with rosuvastatin and of blood pressure lowering with candesartan/hydrochlorothiazide (HCT) and their combination in a wide range of middle aged people, who are at average risk for…